ATE525649T1 - Nachweis von proteinen mit veränderter konformation - Google Patents

Nachweis von proteinen mit veränderter konformation

Info

Publication number
ATE525649T1
ATE525649T1 AT04812753T AT04812753T ATE525649T1 AT E525649 T1 ATE525649 T1 AT E525649T1 AT 04812753 T AT04812753 T AT 04812753T AT 04812753 T AT04812753 T AT 04812753T AT E525649 T1 ATE525649 T1 AT E525649T1
Authority
AT
Austria
Prior art keywords
proteins
detection
altered conformation
prions
conformation
Prior art date
Application number
AT04812753T
Other languages
English (en)
Inventor
Cindy Orser
Anne Grosset
Eugene Davidson
Original Assignee
Adlyfe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adlyfe Inc filed Critical Adlyfe Inc
Application granted granted Critical
Publication of ATE525649T1 publication Critical patent/ATE525649T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT04812753T 2003-12-04 2004-12-03 Nachweis von proteinen mit veränderter konformation ATE525649T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/728,246 US20050026165A1 (en) 2001-05-31 2003-12-04 Detection of conformationally altered proteins and prions
PCT/US2004/040309 WO2005057166A2 (en) 2003-12-04 2004-12-03 Detection of conformationally altered proteins and prions

Publications (1)

Publication Number Publication Date
ATE525649T1 true ATE525649T1 (de) 2011-10-15

Family

ID=34677130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04812753T ATE525649T1 (de) 2003-12-04 2004-12-03 Nachweis von proteinen mit veränderter konformation

Country Status (7)

Country Link
US (3) US20050026165A1 (de)
EP (2) EP2312312B1 (de)
JP (1) JP4815355B2 (de)
AT (1) ATE525649T1 (de)
AU (2) AU2004297579B2 (de)
CA (1) CA2548812A1 (de)
WO (1) WO2005057166A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
AU2002255736B2 (en) * 2001-03-15 2006-08-31 Regenerx, Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (Tbeta4), analogues, isoforms and other derivatives
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
EP1395833B1 (de) * 2001-05-31 2013-02-27 Adlyfe, Inc. Verfahren zum erkennen von inkorrekt gefalteten proteinen
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
US20090130774A1 (en) * 2005-01-13 2009-05-21 David Peretz Elisa assays using prion-specific peptide reagents
US8372593B2 (en) * 2005-02-15 2013-02-12 Adlyfe, Inc. Method for detecting misfolded proteins and prions
EP1931695B1 (de) * 2005-09-09 2013-04-10 Novartis AG Prionspezifische Peptoidreagentien
GB2453191A (en) * 2005-10-18 2009-04-01 Brigham & Womens Hospital Diagnosis of transmissible spongiform encephalopathy
CA2632331C (en) 2005-12-22 2015-02-10 Vib Vzw Molecules with a beta-aggregating region and their use in inducing protein aggregation
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
JP5097206B2 (ja) * 2006-07-28 2012-12-12 エイディーライフ インコーポレイティッド 診断および治療のためのペプチドプローブ
WO2008148751A1 (en) * 2007-06-04 2008-12-11 Vib Vzw Targeted induction of aggregation of proteins with cross beta structures
WO2009117042A1 (en) * 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry non-peptide agents across the blood brain barrier
CN102014967A (zh) * 2008-03-21 2011-04-13 阿德利夫股份有限公司 芘携带肽穿过血脑屏障的用途
EP2282753A1 (de) * 2008-04-30 2011-02-16 Novartis AG Assay für pathogene conformer
DE102008037564A1 (de) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
CN102365295A (zh) * 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽
US20120282169A1 (en) * 2009-11-06 2012-11-08 Adlyfe, Inc. Detection and treatment of traumatic brain injury
CA2834056A1 (en) 2011-04-27 2012-11-01 Adlyfe, Inc. Ocular detection of amyloid proteins
US9618524B2 (en) * 2014-03-26 2017-04-11 Plaxgen Inc. Method, composition, isolation and identification of a plaque particle and related biomarker
GB201411616D0 (en) * 2014-06-30 2014-08-13 Cambridge Entpr Ltd Diagnosis and treatment of neurodegenerative disorders
CN107406513B (zh) * 2014-07-25 2022-07-29 台湾地区“中央研究院” 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
CN104215777B (zh) * 2014-09-18 2016-01-20 首都医科大学宣武医院 一种检测血红蛋白结合磷酸化alpha-突触核蛋白的方法
WO2016048388A1 (en) 2014-09-26 2016-03-31 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
CA3058848A1 (en) 2017-05-09 2018-11-15 Vib Vzw Means and methods for treating bacterial infections

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
ATE177754T1 (de) * 1991-12-03 1999-04-15 Proteus Molecular Design Fragmente von prion proteinen.
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5565186A (en) * 1994-05-13 1996-10-15 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
US5578639A (en) * 1994-07-01 1996-11-26 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
BR9610580A (pt) * 1995-09-14 2000-10-24 Univ California Anticorpos especìficos para prpse nativos
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
WO1997043649A1 (en) * 1996-05-14 1997-11-20 Winnacker Ernst Ludwig CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrP?sc¿
US20060178302A1 (en) * 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
US20010001061A1 (en) * 1997-02-21 2001-05-10 Prusiner Stanley B. Assay for disease related conformation of a protein
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
AU743905B2 (en) * 1997-08-14 2002-02-07 Regents Of The University Of California, The Fluorescent amyloid abeta peptides and uses thereof
JP4223681B2 (ja) * 1997-09-19 2009-02-12 エボテック・アーゲー 病原性タンパク質沈着の基礎構造の会合の測定方法
AU2600499A (en) * 1998-02-13 1999-08-30 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide
US6214565B1 (en) * 1998-10-09 2001-04-10 The Regents Of The University Of California Assay for disease related conformation of a protein and isolating same
US5977324A (en) * 1998-02-20 1999-11-02 The Regents Of The University Of California Process for concentrating protein with disease-related conformation
US6750025B1 (en) * 1998-07-09 2004-06-15 V.I. Technologies, Inc. Method of detecting and isolating prion protein and variants thereof
AU5667599A (en) * 1998-07-27 2000-02-21 Ljl Biosystems, Inc. Apparatus and methods for time-resolved spectroscopic measurements
GB2348203B (en) * 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
AU3474100A (en) 1999-01-25 2000-08-07 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
US6166187A (en) * 1999-03-05 2000-12-26 The Regents Of The University Of California Method of concentrating prion proteins in blood samples
CA2373680C (en) * 1999-05-17 2008-07-29 Conjuchem Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
JP2003506327A (ja) 1999-07-27 2003-02-18 インペリアル・カレッジ・イノベイションズ・リミテッド 疾患の診断および治療に使用できる生物学的物質および方法
GB9917724D0 (en) 1999-07-28 1999-09-29 Medical Res Council Peptides
WO2001014412A1 (en) 1999-08-23 2001-03-01 The Regents Of The University Of California Compounds useful to mimic peptide beta-strands
DE19952955A1 (de) * 1999-11-03 2001-05-17 Acgt Progenomics Ag Verfahren zur Charakterisierung und zur Auftrennung von molekularen Assoziaten
US6399314B1 (en) 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
EP1272509A2 (de) 2000-04-05 2003-01-08 V.I. Technologies, Inc. Peptidische bindstoffe für prione und verfahren zu deren verwendung
SK287768B6 (sk) * 2000-07-07 2011-09-05 Laboratoires Serono Sa Spôsob diagnostiky alebo detekcie konformačného ochorenia, testovanie markera konformačného ochorenia, diagnostický kit a zariadenie na vykonávanie tohto spôsobu
US6780641B2 (en) * 2000-07-10 2004-08-24 University Of British Columbia Immortalized human microglia cell line
US6495335B2 (en) * 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
US7303907B2 (en) * 2001-01-08 2007-12-04 Health Protection Agency Degradation and detection of TSE infectivity
CA2443929C (en) 2001-04-17 2007-12-04 Ista, S.P.A. Detection and quantification of prion isoforms in neurodegenerative diseases using mass spectrometry
WO2002094191A2 (en) * 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
EP1395833B1 (de) * 2001-05-31 2013-02-27 Adlyfe, Inc. Verfahren zum erkennen von inkorrekt gefalteten proteinen
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
WO2003001881A2 (en) * 2001-06-26 2003-01-09 New York State Office Of Mental Health Cell-based high-throughput screening methods
US20050181998A1 (en) * 2001-12-10 2005-08-18 Applied Research Systems Ars Holding N.V. Prion inhibiting peptides and derivatives thereof
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
WO2003073106A2 (en) * 2002-02-28 2003-09-04 Microsens Biophage Limited Binding of pathological forms of prion proteins
DE60325519D1 (de) * 2002-03-01 2009-02-12 Hoffmann La Roche Doppel-transgenisches, nicht-humanes Säugertiermodell für die Alzheimer Krankheit
FR2837401B1 (fr) * 2002-03-25 2004-12-03 Commissariat Energie Atomique Procede de concentration de macromolecules ou agglomerats de molecules ou particules
US7939641B2 (en) * 2002-04-09 2011-05-10 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
JP2004155688A (ja) 2002-04-30 2004-06-03 Biofrontier Kenkyusho:Kk シャペロン活性を有する合成ペプチド、脱炭酸活性の測定方法、伝達性海綿状脳症用薬剤及びその探索方法
CA2496952A1 (en) * 2002-08-23 2004-03-04 Copenhagen Biotech Assets Aps Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
PT1953551E (pt) * 2002-12-03 2014-05-06 Pathogen Removal & Diagnostic Technologies Inc Ligandos a proteína de prião e métodos de uso
US7510848B2 (en) * 2003-04-04 2009-03-31 North Carolina State University Prion protein binding materials and methods of use
US20070054322A1 (en) * 2003-07-31 2007-03-08 Hadasit Medical Research Services & Development Lt Methods and kits for the detection of prion diseases
NZ580256A (en) * 2003-08-13 2011-07-29 Novartis Vaccines & Diagnostic Prion-specific peptide reagents comprising the sequence KKRPKPGG
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
JP3910569B2 (ja) * 2003-08-19 2007-04-25 独立行政法人科学技術振興機構 アミロイドβ蛋白質のアミロイド線維化を増幅するための試薬
WO2005111619A1 (en) * 2004-04-29 2005-11-24 Marc Ramael Method and kit for detecting components in a sample
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
US8372593B2 (en) * 2005-02-15 2013-02-12 Adlyfe, Inc. Method for detecting misfolded proteins and prions
CA2598321A1 (en) * 2005-02-19 2006-08-24 Peoplebio, Inc. Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides
JP5097206B2 (ja) * 2006-07-28 2012-12-12 エイディーライフ インコーポレイティッド 診断および治療のためのペプチドプローブ
WO2009117042A1 (en) 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry non-peptide agents across the blood brain barrier
CN102014967A (zh) 2008-03-21 2011-04-13 阿德利夫股份有限公司 芘携带肽穿过血脑屏障的用途
CN102365295A (zh) 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽
WO2011149917A1 (en) 2010-05-25 2011-12-01 Adlyfe, Inc. STABILIZED AMYLOID- β OLIGOMERS AND USES THEREOF
CA2834056A1 (en) 2011-04-27 2012-11-01 Adlyfe, Inc. Ocular detection of amyloid proteins

Also Published As

Publication number Publication date
AU2010249147A1 (en) 2010-12-23
EP1700096A2 (de) 2006-09-13
US9638702B2 (en) 2017-05-02
EP2312312A2 (de) 2011-04-20
EP1700096A4 (de) 2007-11-21
US20150233948A1 (en) 2015-08-20
CA2548812A1 (en) 2005-06-23
EP1700096B1 (de) 2011-09-21
JP4815355B2 (ja) 2011-11-16
US20050026165A1 (en) 2005-02-03
EP2312312A3 (de) 2011-08-03
AU2004297579A1 (en) 2005-06-23
US20080171341A1 (en) 2008-07-17
WO2005057166A3 (en) 2006-11-30
WO2005057166A2 (en) 2005-06-23
JP2007536502A (ja) 2007-12-13
AU2004297579B2 (en) 2010-09-02
EP2312312B1 (de) 2016-03-02

Similar Documents

Publication Publication Date Title
ATE525649T1 (de) Nachweis von proteinen mit veränderter konformation
ATE424560T1 (de) Marker für neuromyelitis optica
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
ATE490466T1 (de) Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen
EP1687283A4 (de) Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
ATE476525T1 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
DE60328069D1 (de) Test-Photomaske, Streulichtbewertungsverfahren, und Streulichtkompensierungsverfahren
ATE479669T1 (de) Markierungsreagentien, markierte analyten, einschliesslich mischungen davon, und davon abgeleitete fragmentionen und verfahren zu deren analyse
DK2146209T3 (da) Neurodegenerative markører for Alzheimer's sygdom
ATE534905T1 (de) Cop1-moleküle und verwendungen davon
DE602006016589D1 (de) Neue markierungsstrategien für den empfindlichen nachweis von analyten
ATE487142T1 (de) Proteinnachweisreagentien und -verfahren mit farbstoffen und dextrinen
EP2074427A4 (de) Diagnostik-biomolekül(e)
DE602006019404D1 (de) Docetaxel-immuntest
ATE528649T1 (de) Verfahren zum nachweis falsch gefalteter proteine und prionen
EP1788093A4 (de) Gerät, verfahren und kit zum nachweis von bakterien
DE60328055D1 (de) Verfahren zum nachweis von pathogenen mykobakterien in klinischen proben
DE602004016599D1 (de) Abweichungsdetektionsvorrichtung und informationsgerät mit verwendung derselben
DE602006008581D1 (de) Verfahren zur bestimmung von montagebedingungen, vorrichtung zur bestimmung von montagebedingungen und montagevorrichtung
DK2327792T3 (da) Fremgangsmåder og sammensætninger til påvisning af autoimmunsygdomme
DE60219633D1 (de) LÄNGLICHER KANISTER FÜr EINEN AUTOMATISIERTEN MIKROBIOLOGISCHEN ANALYSATOR
DE60216570D1 (de) Verfahren zum nachweis von alzheimer-krankheit
ATE504833T1 (de) Verfahren zur bestimmung des phänotyps von zellen
DE60327121D1 (de) Leseverfahren, und Responder und Interrogator

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties